Marianne De Backer

Biography
Since joining Vir Biotechnology in April 2023, Dr. Marianne De Backer has led the company through a critical strategy evolution sharpening its focus in infectious disease and applying its scientific expertise to critical unmet needs in oncology. Under Dr. De Backer’s leadership, Vir Biotechnology has built a robust clinical pipeline including a late-stage registrational program in hepatitis delta, three Phase 1 masked T-cell engagers tackling a range of solid tumors, and a preclinical pipeline of cancer immunotherapies. Over the course of her career, which began in drug discovery research, Dr. De Backer has been listed as an inventor on seven patents, led the commercial launch of two medicines, and spearheaded more than 250 alliances and acquisitions, several of which resulted in launched medicines. She currently serves on the Board of Directors for the Biotechnology Innovation Organization and as a non-executive director on the board of directors of the Gladstone Foundation.